查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495982

血液诊断市场 – 2024 年至 2029 年预测

Haematology Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 121 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年血液诊断市场规模为65.83亿美元，复合年增长率为6.18%，2029年将达100.12亿美元。

血液学是对血液和血液相关疾病的研究。血液相关疾病和病症（例如贫血、血癌和血栓）的诊断属于血液学诊断的范畴。在过去几年中，此类血液疾病的盛行率一直在增加，是预计在预测期内推动血液诊断市场成长的关键因素之一。

此外，血液诊断技术的进步使诊断变得更加方便和高效。市场持续的技术创新预计也将在未来几年进一步促进市场成长。此外，全球老年人口的成长正在导致患者数量的增加，这是预计在评估期间推动需求的另一个重要因素。

市场驱动因素：

  • 由于血液疾病的增加，血液诊断市场预计将快速成长。

贫血、血友病、血癌和血栓等各种类型的血液疾病在全世界不断增加。贫血是一种如此普遍的疾病，其外显率不断增加。根据世界银行资料，6至59个月儿童贫血盛行率从2010年的10.4%上升至2019年的13.2%。在芬兰，这一比例从2010年的10%上升到2019年的11.8%，在丹麦，这一比例从2010年的12.6%上升到2019年的14.5%。

此外，根据世界银行的资料，全球育龄或15岁至59岁女性贫血盛行率已从2013年的28.5%跃升至2019年的29.9%。此外，血癌病例正在快速增加，预计将在预测期内推动血液诊断市场的成长。

根据美国癌症协会估计，2021 年美国将新增 61,090 例白血病病例。此外，同期美国的白血病发生率男性从每 10 万人口 18 例增加到 2017 年的约 20 例，女性从每 10 万人 10.8 例增加到 11.8 例。澳洲白血病基金会预测，血癌患者人数将从 2020 年的 11 万人增加到 2035 年的 275,000 多人。

  • 预计老年人口的成长将推动血液学诊断的需求

过去几年，世界老年人口持续成长，预计未来几年将持续成长。随着老年人口老化，贫血和白血病等血液疾病的风险增加。定期血液学评估对于早期发现和治疗至关重要。

心血管疾病和糖尿病等慢性疾病也会影响血液学参数，因此血液诊断对于监测其对血液成分的影响并识别相关併发症至关重要。在美国，65岁以上人口占总人口的比例从2010年的12.98%上升到2020年的16.63%（资料来源：世界银行）。中国也是一个老年人口快速成长的国家。

65岁以上人口将从2010年的1,080.12亿增加到2020年的1,688.64亿，10年间成长36%以上。在法国，65岁以上人口数从2010年的109.58亿快速成长至2020年的139.86亿，成长超过27%。 （图片来源：世界银行）

人口老化预计将持续下去，这将极大地导致患者数量的增加。预计这将在评估期间对全球血液诊断市场产生积极影响。

北美地区占据主要市场占有率

从地理位置来看，由于诊断中心丰富，北美地区预计将占据主要市场占有率。此外，先进的医疗系统使人们更容易接受血液疾病的诊断，导致该地区血液诊断市场规模庞大。

由于医疗设施的改善使更多人能够获得所需的医疗服务，预计北美地区将显着成长。老年人口和总人口的增加是预计在预测期内推动该地区血液诊断市场成长的其他重要原因。

北美先进的医疗基础设施、血液疾病的高盛行率以及慢性病盛行率的上升正在推动对先进血液诊断的需求。该地区对这些疾病的早期诊断和监测的重视正在推动对血液诊断的需求。自动分析仪和分子诊断等诊断技术的进步正在吸引医疗保健提供者投资最新的解决方案。就地检验也变得越来越普及，有助于市场成长。

主要发展

  • 2024 年 2 月 - Sysmex Corporation 和 CellaVision 签订了一项策略合作协议，透过扩展其产品组合以包含下一代细胞形态分析仪来推进血液学解决方案。双方合作始于 20 年前的血液学领域，该领域分析红血球、白血球和其他血球。该协议有效期至 2038 年，利用 Sysmex 在血液学领域测试工作流程效率和标准化方面的专业知识，同时最大限度地发挥与 CellaVision 数位影像处理和分析技术的协同效应。
  • 2023 年 8 月 - Abbott 的 Alinity h 系列血液检测系统获得 FDA 批准。作为 Alinity 诊断产品系列的一部分，该系统使实验室能够执行全血球计数 (CBC)。该系统包括自动血液分析仪、切片机和染色机。 Alinity h 系列描述了医生可以用来快速有效地护理患者的广泛测试。优点包括每小时能够处理多达 119 个 CBC 结果、安装空间小以及集中的结果和控制功能。
  • 2023 年 7 月 - Sysmex Europe SE 推出其实验室血液学旗舰产品线 XR 系列。该产品线建立在其前身 XN 系列的可靠性和技术之上。列出了新资产和通量改进以满足实验室需求。 XR系列在日本推出，融合了全球客户的优势。血液学实验室可以自动执行条码读取、试管分类、抹片管理和试剂管理。总裁兼执行长 Alain Baverel 表示，XR 系列是实验室的可靠选择，旨在继续为血液检测提供可靠的诊断和服务。

主要市场区隔

按测试类型

  • 血红素
  • 血球计数
  • 血小板功能
  • 分血器
  • 其他的

按最终用户

  • 医院和诊所
  • 诊断中心
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 其他的
  • 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章血液诊断市场：依测试类型

  • 介绍
  • 血红素
  • 血球计数
  • 血小板功能
  • 分血器
  • 其他的

第六章血液诊断市场：依最终用户分类

  • 介绍
  • 医院和诊所
  • 诊断中心
  • 其他的

第七章血液诊断市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Bio-Rad Laboratories, Inc.
  • Boule Diagnostics AB
  • Abbott Laboratories
  • Diatron
  • Biosystems SA
  • F. Hoffmann-La Roche Ltd
  • Horiba, Ltd.
  • Erba Diagnostics Mannheim GmbH
  • Ortho Clinical Diagnostics
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
简介目录
Product Code: KSI061611962

The haematology diagnostics market is evaluated at USD6.583 billion for the year 2022, growing at a CAGR of 6.18% to reach the market size of USD10.012 billion by the year 2029.

Haematology is the study of blood and blood-related diseases. The diagnosis of diseases or disorders related to blood, including anemia, blood cancer, and blood clots, among others, comes under the umbrella of haematology diagnostics. The incidences of such blood disorders have been increasing over the past years and are one of the major factors anticipated to drive the haematology diagnostics market growth during the forecast period.

Furthermore, the technological advancements in haematology diagnostics have made it more convenient and efficient. The continuous innovation in the market is expected to augment the market growth further in the coming years as well. Moreover, the growing geriatric population worldwide leads to an increase in the number of patients and is another prominent factor anticipated to boost the demand during the assessment period.

Market Drivers:

  • Rising incidences of blood disorders is expected to surge the Haematology Diagnostics Market.

Various kinds of blood disorders are on the rise worldwide, including anemia, hemophilia, blood cancer, and blood clots, among others. Anemia is one such widely prevalent disorder that is increasing its pervasiveness. According to data from the World Bank, the prevalence of anemia among children aged 6-59 months has increased from 10.4% in 2010 to 13.2% in 2019. In Finland, it has increased from 10% in 2010 to 11.8% in 2019, while in Denmark, it reached 14.5% in 2019, rising from 12.6% in 2010.

Furthermore, the data from the World Bank shows that the global prevalence of anemia among women of reproductive age or women aged 15 to 59 years has jumped from 28.5% in 2013 to 29.9% in 2019. Moreover, the cases of blood cancer are increasing at a fast pace, which is expected to propel the haematology diagnostics market growth during the forecast period.

The American Cancer Society states that the estimated new cases of leukemia in the United States in 2021 will be 61,090. It also states that the incidence rate of leukemia in the U.S. has increased from 18 in 2009 to around 20 per 100,000 population in 2017 for males and from 10.8 to 11.8 for females during the same time period. The Leukaemia Foundation in Australia projects the number of blood cancer cases from 110,000 in 2020 to more than 275,000 in 2035.

  • Growing geriatric population is anticipated to drive the demand for haematology diagnostics

The global elderly population has been rising over the past years and is projected to further grow in the coming years as well. As the geriatric population ages, the risk of hematological disorders like anemia and leukemia increases. Regular haematological assessments are crucial for early detection and management.

Chronic diseases like cardiovascular diseases and diabetes also impact haematological parameters, making haematology diagnostics essential for monitoring their effects on blood composition and identifying associated complications. In the United States, the share of the elderly population aged 65 and above in the total population has increased from 12.98% in 2010 to 16.63% in 2020, as per the World Bank. China is another country witnessing a rapid rise in its geriatric population.

The population aged 65 and above reached 168.864 billion in the country in 2020, jumping from 108.012 billion in 2010, witnessing a growth of more than 36% over a decade. In France, the population aged 65 and above has surged from 10.958 billion in 2010 to 13.986 billion in 2020, growing by more than 27%. (Source: World Bank)

The population is anticipated to continue to age in the coming years, contributing significantly to the rise in the number of patients. This is anticipated to have a positive impact on the global haematology diagnostics market during the assessment period.

The North American region holds a significant market share

Geographically, the North American region is projected to hold a significant market share owing to the presence of diagnostic centers in abundance. Furthermore, an advanced healthcare system makes it simple for people to get their blood disorders diagnosed and consequently results in a significant market size of haematology diagnostics in the region.

The North American region is projected to witness substantial growth due to improved medical facilities leading to a higher number of people getting access to the needed healthcare services. The rising geriatric population and the overall population are other prominent reasons anticipated to propel the market growth of haematology diagnostics in this region during the forecast period.

North America's advanced healthcare infrastructure, high prevalence of haematological disorders, and rising incidence of chronic diseases drive demand for advanced haematology diagnostics. The region's focus on early diagnosis and monitoring of these conditions drives the demand for haematology diagnostics. Technological advancements in diagnostics, such as automated analyzers and molecular diagnostics, attract healthcare providers to invest in modern solutions. Point-of-care testing is also gaining popularity, contributing to market growth.

Key Developments:

  • February 2024- Sysmex Corporation and CellaVision entered a strategic alliance agreement to advance haematology solutions by expanding their portfolio, including next-generation cell morphology analyzers. The partnership began 20 years ago in the field of haematology, which analyzes red, white, and other blood cells. The agreement will extend until 2038 and will utilize Sysmex's expertise in enhancing efficiency and standardization of testing workflow in the haematology field, while maximizing synergies with CellaVision's digital imaging and analysis technologies. The goal is to enhance efficiency and standardization in the testing workflow and improve clinical value in supporting diagnoses.
  • August 2023- Abbott received FDA clearance for its Alinity h-series haematology system, allowing laboratories to run complete blood counts (CBC) as part of its Alinity family of diagnostic products. The system includes an automated haematology analyzer and an integrated slide maker and stainer. The Alinity h-series offers a wide array of tests doctors can use to quickly and effectively care for their patients. It offers advantages such as processing up to 119 CBC results per hour, requiring less floor space, and centralized results and control functions.
  • July 2023- Sysmex Europe SE introduced the XR-Series, its flagship product line for laboratory haematology. The line builds on the reliability and technology of its predecessor, the XN-Series. It offers new assets and improved throughput to meet laboratory needs. Launched in Japan, the XR-Series incorporates the strengths of customers worldwide. Haematology labs can automate barcode reading, tube sorting, smear management, and reagent management. President and CEO Alain Baverel aim to continue providing reliable diagnostics and services in haematology, stating that the XR-Series is a reliable option for labs.

Key Market Segmentation:

By Test Type

  • Hemoglobin
  • Blood Count
  • Platelet Function
  • Hematocrit
  • Others

By End-User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HAEMATOLOGY DIAGNOSTICS MARKET BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Hemoglobin
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Blood Count
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Platelet Function
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Hematocrit
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Others
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. HAEMATOLOGY DIAGNOSTICS MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals and Clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Diagnostic Centers
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. HAEMATOLOGY DIAGNOSTICS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Test Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Test Type
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Test Type
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. UK
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Others
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Test Type
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Test Type
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. India
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. Japan
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Bio-Rad Laboratories, Inc.
  • 9.2. Boule Diagnostics AB
  • 9.3. Abbott Laboratories
  • 9.4. Diatron
  • 9.5. Biosystems S.A.
  • 9.6. F. Hoffmann-La Roche Ltd
  • 9.7. Horiba, Ltd.
  • 9.8. Erba Diagnostics Mannheim GmbH
  • 9.9. Ortho Clinical Diagnostics
  • 9.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.